Key Highlights

  • Acadia Pharmaceuticals (NASDAQ:ACAD) fell 22.28% on November 9, 2026, touching a 52-week low near USD 18, after it reported third-quarter results.
  • Third-quarter Revenue of about USD 342 million beat the roughly USD 332 million consensus, and adjusted Earnings Per Share of USD 0.31 topped the USD 0.20 forecast.
  • Investor focus stayed on remlifanserin, the Alzheimer's disease psychosis candidate that narrowly missed its primary endpoint in a Phase 2 study reported in September.
  • Full-year 2026 revenue guidance was narrowed to USD 1.265 billion to USD 1.295 billion, with DAYBUE sales up 39% and NUPLAZID up about 12% in the quarter.

A Beat That Did Not Help

On the commercial side, the quarter at Acadia Pharmaceuticals (NASDAQ:ACAD) was solid. DAYBUE, its treatment for Rett syndrome, generated net sales of about USD 140 million, up 39% from a year earlier, and NUPLAZID, for Parkinson's disease psychosis, delivered about USD 202 million, up about 12% on an adjusted basis. Total revenue of about USD 342 million beat expectations, and adjusted earnings per share of USD 0.31 were well above forecasts. Management narrowed its full-year revenue range to USD 1.265 billion to USD 1.295 billion. Despite these figures, the stock fell 22.28% to its lowest level in a year, which shows that the market is valuing the company on its pipeline rather than on its current products. NUPLAZID faces eventual generic competition, so new growth drivers are critical to the long-term valuation and to sustaining revenue growth beyond the end of the decade.

Why Remlifanserin Matters So Much

Remlifanserin is the company's main bet on a much larger market. Alzheimer's disease psychosis, which involves hallucinations and delusions, affects a large and growing population with few approved treatments. In the Phase 2 portion of the RADIANT study, reported in September 2026, 326 patients received 60 mg, 30 mg or placebo for six weeks. The 60 mg dose reduced symptoms by 12.6 points against 10.4 for placebo, a difference that narrowly missed statistical significance with a p-value of 0.0603. A key secondary measure of overall severity did reach nominal significance. The company dropped the 30 mg arm and is carrying 60 mg into Phase 3. The sharp fall on November 9, 2026 indicates that investors remain unconvinced that the planned Phase 3 design can deliver a clear win, particularly given the high placebo response that is common in psychiatric trials in elderly patients.

Risks and Upcoming Catalysts

The precise trigger for the size of the November 9 decline was not spelled out in the company's update, which adds to uncertainty. Shares were already down more than 20% in 2026 before the drop. The main risks for Acadia Pharmaceuticals (NASDAQ:ACAD) are a Phase 3 failure for remlifanserin, slower DAYBUE growth and future generic pressure on NUPLAZID. The safety profile so far has been clean, with no new signals, low rates of somnolence and nausea, and no QT prolongation. Investors will look to additional remlifanserin data at a major Alzheimer's conference in Boston from November 16 to 19, 2026, details of the Phase 3 protocol and continued DAYBUE growth, including a new formulation. A Phase 2 study in Lewy body dementia is expected to read out in early 2028.

Where Things Stand

Acadia fell 22.28% to a 52-week low on November 9, 2026 even though third-quarter revenue and earnings beat expectations, as doubts over remlifanserin's path in Alzheimer's disease psychosis dominated sentiment. DAYBUE and NUPLAZID continue to grow. New remlifanserin data at the November 16 to 19 conference and the Phase 3 design are the next catalysts.